Addex announces plan to implement ads ratio change

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, october 6, 2023 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it plans to change the ratio of its american depositary shares (“adss”) to its ordinary shares (the “ads ratio”) from the current ads ratio of one (1) ads to six (6) ordinary shares to a new ads ratio of one (1) ads to one hundred and twenty (120) ordinary shares (the “ads ratio change”).
ADXN Ratings Summary
ADXN Quant Ranking